Rachel Halpern, PhD, MPH
Director, Therapeutic Lead
Central Nervous System and Behavioral Health
Dr. Rachel Halpern joined Optum HEOR in 2005. As HEOR therapeutic lead for central nervous system and behavioral health (CNS/BH), Dr. Halpern conducts and oversees retrospective CNS/BH studies based on administrative claims data and electronic health record data.
Before joining Optum, Dr. Halpern had eight years of health research experience in areas including military hospital market areas, managed care for persons with disabilities and implementation of risk adjustment methodologies.
Dr. Halpern earned her Master of Public Health from the University of Michigan and her doctorate's in health services research and policy at the University of Minnesota. She has authored or been a co-author on over 30 articles.
Ng-Mak D, Halpern R, Rajagopalan K, Loebel A. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics. Curr Med Res Opin. 2018 Apr 22:1-9.
Halpern R, Shah SN, Cappelleri JC, Masters ET, Clair A. Evaluating guideline-recommended pain medication use among patients with newly diagnosed fibromyalgia. Pain Pract. 2016 Nov;16(8):1027-1039.
Halpern R, Nadkarni A, Kalsekar I, et al. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. Ann Pharmacother. 2013;47(7-8):933-945.
Halpern R, Kothari S, Fuldeore M, Zarotsky V, Porter V, Dabbous O, Goldstein JL. GERD-Related Health Care Utilization, Therapy, and Reasons for Transfer of GERD Patients Between Primary Care Providers and Gastroenterologists in a US Managed Care Setting. Dig Dis Sci. 2010 Feb;55(2):328-37.
Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs. J Clin Rheumatol. 2009 Feb;15(1):3-7.
HEOR, Health Economics Outcomes Research, Health Economics, CNS, Central Nervous System, Behavioral Health